A simulation-based technology for stochastic modeling, sensitivity analysis and design optimization, aimed at development of next-generation micro-fluidic devices for biomedical applications.

一种用于随机建模、灵敏度分析和设计优化的模拟技术，旨在开发用于生物医学应用的下一代微流体设备。

• 批准号: 10323474
• 负责人: GAURAV KEWLANI
• 金额: $ 23.21万
• 依托单位: SOFTWORTHY LLC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2023-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10323474
• 关键词: Accounting; Address; Adopted; Affect; Air; Algorithms; Artificial Intelligence; Automobile Driving; Biology; Biomedical Engineering; Cells; Cessation of life; Characteristics; Chemicals; Chemistry; Complex; Comprehensive Health Care; Computer software; Development; Device Designs; Devices; Diagnosis; Diagnostic; Discipline; Disease; Disease Outbreaks; Drug Delivery Systems; Elements; Engineering; Ensure; Environmental Risk Factor; Epidemic; Equipment Malfunction; Evaluation; Exhibits; Fiber; Finite Element Analysis; Food Safety; Formulation; Fostering; Genes; Guidelines; Health; Health Care Sector; Industry; Infection; Investigation; Knowledge; Lead; Methodology; Methods; Microfluidic Microchips; Microfluidics; Modeling; Monte Carlo Method; Morbidity - disease rate; Outcome; Output; Pathogen detection; Patients; Performance; Pharmaceutical Preparations; Physics; Play; Polynomial Models; Primary Health Care; Probability; Process; Productivity; Public Health; Quality Control; Rapid screening; Resolution; Resources; Role; Scheme; Sensitivity and Specificity; Software Design; Space Explorations; Specific qualifier value; System; Techniques; Technology; Temperature; Testing; Therapeutic; Thermal Conductivity; Uncertainty; Variant; Work; base; clinical decision-making; clinically relevant; commercial application; cost; design; detection limit; detection sensitivity; digital; disability; disability-adjusted life years; drug discovery; drug synthesis; effective therapy; engineering design; global health; graphical user interface; improved; innovation; insight; knowledge base; microfluidic technology; mortality; multidisciplinary; next generation; novel; point-of-care diagnostics; portability; practical application; prospective; prototype; rapid detection; reconstitution; recurrent neural network; research and development; response; scientific computing; screening; simulation; simulation software; software systems; therapeutically effective; tool; Accounting; Address; Adopted; Affect; Air; Algorithms; Artificial Intelligence; Automobile Driving; Biology; Biomedical Engineering; Cells; Cessation of life; Characteristics; Chemicals; Chemistry; Complex; Comprehensive Health Care; Computer software; Development; Device Designs; Devices; Diagnosis; Diagnostic; Discipline; Disease; Disease Outbreaks; Drug Delivery Systems; Elements; Engineering; Ensure; Environmental Risk Factor; Epidemic; Equipment Malfunction; Evaluation; Exhibits; Fiber; Finite Element Analysis; Food Safety; Formulation; Fostering; Genes; Guidelines; Health; Health Care Sector; Industry; Infection; Investigation; Knowledge; Lead; Methodology; Methods; Microfluidic Microchips; Microfluidics; Modeling; Monte Carlo Method; Morbidity - disease rate; Outcome; Output; Pathogen detection; Patients; Performance; Pharmaceutical Preparations; Physics; Play; Polynomial Models; Primary Health Care; Probability; Process; Productivity; Public Health; Quality Control; Rapid screening; Resolution; Resources; Role; Scheme; Sensitivity and Specificity; Software Design; Space Explorations; Specific qualifier value; System; Techniques; Technology; Temperature; Testing; Therapeutic; Thermal Conductivity; Uncertainty; Variant; Work; base; clinical decision-making; clinically relevant; commercial application; cost; design; detection limit; detection sensitivity; digital; disability; disability-adjusted life years; drug discovery; drug synthesis; effective therapy; engineering design; global health; graphical user interface; improved; innovation; insight; knowledge base; microfluidic technology; mortality; multidisciplinary; next generation; novel; point-of-care diagnostics; portability; practical application; prospective; prototype; rapid detection; reconstitution; recurrent neural network; research and development; response; scientific computing; screening; simulation; simulation software; software systems; therapeutically effective; tool

During an epidemic, testing numerous patients puts a heavy burden on the healthcare sector, while infections continue to rise in the absence of a treatment. In such a scenario, micro-fluidics technology can be used to develop affordable point-of-care diagnostic tools for detecting infected patients early, and effective drug discovery platforms for synthesizing therapeutic drugs. The development of such devices is extremely challenging, needing expertise in multiple disciplines (e.g. physics, chemistry, biology), and understanding the interplay between variables that influence operating performance requires computational assistance. While advanced design software may be adopted to simulate the performance of such devices, precise knowledge of prediction reliability is of paramount importance to ensure their suitability for clinical decision-making. Therefore, the long term objectives of this project are to commercially introduce a new paradigm of digital engineering design that focuses on evaluating the fluctuations in performance outputs due to variability in input parameters and to demonstrate the relevance of such a simulation-based technology through specific application to development of micro-fluidic biomedical devices. The envisioned proof-of-concept is a modular computational system with practical commercial applications in the healthcare sector that demonstrates how scientific computing, numerical simulation & artificial intelligence modeling approaches can lead to an increased understanding of the performance of a micro-fluidic system subject to operating uncertainty, and enable robust design optimization. The proposed approach is to employ innovative stochastic spectral methods & advanced numerical schemes to conduct computationally efficient, high fidelity simulations involving uncertainty quantification & propagation, model sensitivity analysis, and finite element analysis for the engineering evaluation of progressively complex micro-fluidic device designs, and to incorporate artificial intelligence based meta-modeling techniques to perform design space exploration for performance improvement of such devices. The R&D efforts would establish the technical merits & feasibility of a simulation- based technology for predictive stochastic analysis & multi-disciplinary engineering evaluation of novel micro- fluidic devices that addresses the need for efficient & accurate performance assessment of such devices in practical (often uncertain/variable) operating scenarios. It could subsequently be utilized by biomedical engineers to foster the rapid development of robust next-generation devices that operate reliably within desired operating performance specifications, such as diagnostic tools with improved detection sensitivity & specificity, and drug discovery platforms with enhanced reconstitution of complex cellular interactions. These can play a crucial role in rapid short-term response to control the spread of infections & to mitigate disease outbreaks, while also offering improved solutions for enhancing long-term access to primary healthcare & comprehensive disease treatment, thereby significantly improving public health, particularly in resource constrained settings.

在流行病中，对许多患者进行测试给医疗保健部门带来了沉重的负担，而感染 在没有治疗的情况下继续上升。在这种情况下，微流体技术可用于 开发负担得起的护理点诊断工具，用于早日检测受感染的患者和有效的药物 合成治疗药物的发现平台。这种设备的开发极为 具有挑战性，需要多个学科的专业知识（例如物理，化学，生物学），并理解 影响操作绩效的变量之间的相互作用需要计算援助。尽管 可以采用高级设计软件来模拟此类设备的性能，精确的知识 预测可靠性对于确保其适合临床决策的适用性至关重要。 因此，该项目的长期目标是在商业上引入新的数字范式 工程设计的重点是评估由于输入的可变性而导致性能输出的波动 参数并通过特定来证明这种基于模拟的技术的相关性 用于开发微氟生物医学设备。设想的概念验证是一个模块化 在医疗保健领域具有实际商业应用的计算系统，证明了如何 科学计算，数值模拟和人工智能建模方法可以导致 增加对微荧光系统的性能的了解，受到运营不确定性的影响，并且 启用强大的设计优化。提出的方法是采用创新的随机光谱方法 和高级数值方案，以进行计算高效，高保真模拟涉及 不确定性定量和传播，模型灵敏度分析和有限元分析 逐步复杂的微富集设备设计的工程评估，并合并人造 基于智能的元模型技术以执行性能的设计空间探索 改进此类设备。研发工作将确定模拟的技术优点和可行性 - 基于预测性随机分析和多学科工程评估的基于新型微型的技术评估 流体设备，以解决此类设备在 实用（通常不确定/可变）的操作场景。随后可以通过生物医学来利用 工程师促进可靠地运行的强大下一代设备的快速开发 操作性绩效规格，例如具有提高检测灵敏度和特异性的诊断工具， 以及具有增强复杂细胞相互作用的重构的药物发现平台。这些可以玩 在快速短期反应中至关重要的作用，以控制感染的传播和减轻疾病暴发的蔓延， 同时还提供改进的解决方案，以增强长期获得初级医疗保健和全面的访问 疾病治疗，从而大大改善公共卫生，尤其是在资源受限的环境中。